EMEA-001877-PIP03-17

Key facts

Active substance
Fremanezumab
Therapeutic area
Neurology
Decision number
P/0386/2017
PIP number
EMEA-001877-PIP03-17
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Prevention of cluster headache
Route(s) of administration
  • Intravenous use
  • Subcutaneous use
Contact for public enquiries
Teva GmbH
Tel. +491726277979
E-mail: info.era-clinical@teva.de
Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating